Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis

Immunobiology

Volumn 218, Issue 5, 2013, Pages 745-754

  Smith, Kenneth ^a   Muther, Jennifer J ^a   Duke, Angie L ^a   McKee, Emily ^a   Zheng, Nai Ying ^b   Wilson, Patrick C ^b   James, Judith A ^a,c  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody secreting cells; B cell memory; Human monoclonal antibodies; Pneumovax; Streptococcus pneumoniae

Indexed keywords

CELL WALL POLYSACCHARIDE VACCINE; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; PVAX1 P1D02 ANTIBODY; PVAX1 P4B03 ANTIBODY; PVAX1 P6D04 ANTIBODY; PVAX2 P3C04 ANTIBODY; PVAX2 P5A06 ANTIBODY; PVAX2 P6B03 ANTIBODY; PVAX2 P7D03 ANTIBODY; PVAX3 P1A03 ANTIBODY; PVAX3 P1E01 ANTIBODY; PVAX4 P1A06 ANTIBODY; PVAX4 P1B01 ANTIBODY; PVAX4 P1C03 ANTIBODY; PVAX4 P1C04 ANTIBODY; PVAX4 P2C04 ANTIBODY; PVAX4 P2D03 ANTIBODY; PVAX4 P2F01 ANTIBODY; PVAX4 P2G06 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CASE REPORT; CROSS REACTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCING CELL; MALE; MUTATION RATE; OPSONIZATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SEROTYPE; SOMATIC HYPERMUTATION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIBODY-PRODUCING CELLS; CLONE CELLS; CROSS REACTIONS; FEMALE; HL-60 CELLS; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84875676633     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.08.278     Document Type: Article

References (23)

1. Anttila M., Voutilainen M., Jäntti V., Eskola J., Käyhty H. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. 1999, 118:402-407.
2. Baxendale H.E., Davis Z., White H.N., Spellerberg M.B., Stevenson F.K., Goldblatt D. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur. J. Immunol. 2000, 30:1214-1223.
3. Baxendale H.E., Goldblatt D. Correlation of molecular characteristics, isotype, and in vitro functional activity of human antipneumococcal monoclonal antibodies. Infect. Immun. 2006, 74:1025-1031.
4. Baxendale H.E., Johnson M., Keating S.M., Ashton L., Burbidge P., Woodgate S., Southern J., Miller E., Goldblatt D. Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. Vaccine 2010, 28:6915-6922.
5. Casal J., Aguilar L., Jado I., Yuste J., Giménez M.J., Prieto J., Fenoll A. Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of β-lactams in a mouse sepsis model. Antimicrob. Agents Chemother. 2002, 46:1340-1344.
6. 197 conjugate vaccine. Immunology 2006, 119:328-337.
7. Harris S., Tsao H., Ashton L., Goldblatt D., Fernsten P. Avidity of the Immunoglobulin G response to a Neisseria meningitides group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays. Clin. Vaccine Immunol. 2007, 14:397-403.
8. Lee C.-J., Koizumi K., Henrichsen J., Perch B., Lin C.S., Egan W. Capsular polysaccharides of nongroupable streptococci that cross-react with pneumococcal group 19. J. Immunol. 1984, 133:2706-2711.
9. Marchese R.D., Jain N., Antonello J., Mallette L., Butterfield-Gerson K., Raab J., Burke P., Schulman C., Adgate H., Sikkema D., Chirmule N. Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the Pneumovax 23 vaccine: assay operating characteristics and correlation to the WHO international assay. Clin. Vaccine Immunol. 2006, 13:905-912.
10. Martinez J., Pilishvili T., Barnard S., Caba J., Spear W., Romero-Steiner S., Carlone G.M. Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitides serogroup A, C, Y, or W135 polysaccharide correlates with serum bactericidal activity. Clin. Diagn. Lab. Immunol. 2002, 9:485-488.
11. Nieminen T., Käyhty H., Virolainen A., Eskola J. Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response. Vaccine 1998, 16:313-319.
12. Nieminen T., Eskola J., Käyhty H. Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum. Vaccine 1998, 16:630-636.
13. Park S., Parameswar A., Demchenko A., Nahm M. Identification of a simple chemical structure associated with protective human antibodies against multiple pneumococcal serogroups. Infect. Immun. 2009, 77:3374-3379.
14. Pickering J.W., Hoopes J., Groll M., Romero H., Wall D., Sant H., Astill M., Hill H. A 22-plex chemiluminescent microarray for pneumococcal antibodies. Am. J. Clin. Pathol. 2007, 128:23-31.
15. Soininen A., Van Den Dobbelsteen G., Oomen L., Käyhty H. Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?. Clin. Diagn. Lab. Immunol. 2000, 7:468-476.
16. Smith K., Garman L., Wrammert J., Zheng N.Y., Capra J.D., Ahmed R., Wilson P.C. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 2009, 4:372-384.
17. Smith K., Crowe S.R., Garman L., Guthridge C.J., Muther J.J., McKee E., Farris A.D., Guthridge J.M., Wilson P.C., James J.A. Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Vaccine 2012, 30(28):4276-4283.
18. Usinger W.R., Lucas A.H. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 1999, 67:2366-2370.
19. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., Zheng N., Mays I., Garman L., Helms C., James J., Air G., Capra J.D., Ahmed R., Wilson P.C. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671.
20. Xu Q., Abeygunawardana C., Ng A.S., Sturgess A.W., Harmon B.J., Hennessey J.P. Characterization and quantification of C-polysaccharide in Streptococcus pneumoniae capsular polysaccharide preparations. Anal. Biochem. 2005, 336:262-272.
21. Yuste J., Jado I., Giménez M.J., Aguilar L., Molder F., Fenoll A., Casal J. Modification of bacteraemia by specific antibodies and relation with mortality in a pneumococcal mouse sepsis model. Clin. Exp. Immunol. 2002, 128:411-415.
22. Zhou J., Lottenbach K.R., Barenkamp S.J., Lucas A.H., Reason D.C. Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F. Infect. Immun. 2002, 70:4083-4091.
23. Zhou J., Lottenbach K.R., Barenkamp S.J., Reason D.C. Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 6B. Infect. Immun. 2004, 72:3505-3514.